

NIGERIA - Pentavalent Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nigeria						
2. Grant number: 1720-NGA-04c-X						
3. Date of Decision Letter: 16 December 2016						
4. Date of the Partnership Framework Agreement: 9 January 2014						
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine						
6. Vaccine type: Pentavalent						
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID						
8. Programme duration⁵: 2012 - 2020						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)						
	2012-2016	2017	2018	2019	2020	Total ⁶
Programme Budget (US\$)	137,052,081 ⁷	18,612,000	16,436,500	13,347,000	9,771,500	195,219,081
10. Vaccine introduction grant (in US\$): Not applicable.						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁸						
Type of supplies to be purchased with Gavi funds in each year	2012-2016	2017				
Number of Pentavalent vaccines doses		15,549,500				
Annual Amounts (US\$)	US\$137,052,081 ⁹	US\$18,612,000				
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
13. Self-procurement: Not applicable.						

⁵ This is the entire duration of the Programme.

⁶ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁷ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁸ This is the amount that Gavi has approved.

⁹ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1720-NGA-04c-X-C

According to the co-financing policy, the Country falls within the group Accelerated transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	12,431,500	16,714,000	20,335,500	24,594,000
Number of AD syringes	10,133,700			
Number of safety boxes	111,500			
Value of vaccine doses (US\$)	14,575,519			
Total co-financing payments (US\$) (including freight)	15,390,000	20,703,500	25,189,500	30,464,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May and August
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Country shall provide the following clarifications to Gavi*:

Not applicable.

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: None.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

16 December 2016

NIGERIA - Pneumococcal Vaccine Support

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nigeria						
2. Grant number: 1720-NGA-12b-X						
3. Date of Decision Letter: 16 December 2016						
4. Date of the Partnership Framework Agreement: 9 January 2014						
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine						
6. Vaccine type: Pneumococcal						
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID						
8. Programme duration¹: 2014 - 2020						
9. Programme Budget (indicative): subject to the terms of the Partnership Framework Agreement						
10.						
	2014-2016	2017	2018	2019	2020	Total ²
Programme Budget (US\$)	144,740,500 ³	52,919,000	48,579,000	43,312,000	37,849,500	327,400,000
11. Vaccine introduction grant (in US\$): .Not applicable.						
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)						
Type of supplies to be purchased with Gavi funds in each year	2014-2016	2017				
Number of Pneumococcal vaccines doses		15,110,800				
Annual Amounts (US\$)	US\$144,740,500 ⁴	US\$52,919,000				
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
14. Self-procurement: Not applicable.						
15. Co-financing obligations: Reference code: 1720-NGA-12b-X-C According to the co-financing policy, the Country falls within the group Accelerated transition.						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the consolidated amount for all previously approved years. .Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	7,745,400	11,858,400	15,623,600	19,662,200
Number of AD syringes	7,619,600			
Number of safety boxes	83,825			
Value of vaccine doses (US\$)	US\$23,622,969			
Total co-financing payments (US\$) (including freight)	US\$24,228,000	US\$ 37,098,500	US\$ 48,877,500	US\$ 61,512,500

16. Operational support for campaigns: Not applicable

17. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May and August
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

18. Financial clarifications: Country shall provide the following clarifications to Gavi*:


]

Not applicable.

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

19. Other conditions: None

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

16 December 2016

NIGERIA -Inactivated Polio Vaccine (IPV) support
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nigeria								
2. Grant number: 1718-NGA-25c-X								
3. Date of Decision Letter: 16 December 2016								
4. Date of the Partnership Framework Agreement: 9 January 2014								
5. Programme title: NVS, IPV routine								
6. Vaccine type: Inactivated Polio Vaccine (IPV)								
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID								
8. Programme duration²: 2015 - 2018								
<p>9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i></p> <table border="1"> <thead> <tr> <th></th> <th>2015-2016</th> <th>2017</th> <th>Total³</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$21,671,374</td> <td>US\$7,261,000</td> <td>US\$28,932,374</td> </tr> </tbody> </table>		2015-2016	2017	Total ³	Programme Budget (US\$)	US\$21,671,374	US\$7,261,000	US\$28,932,374
	2015-2016	2017	Total ³					
Programme Budget (US\$)	US\$21,671,374	US\$7,261,000	US\$28,932,374					
10. Vaccine introduction grant: US\$5,847,947 was disbursed on 19 February 2015.								
<p>11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)⁴</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Gavi funds in each year</th> <th>2017</th> </tr> </thead> <tbody> <tr> <td>Number of IPV vaccines doses</td> <td>8,101,700</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$7,261,000</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2017	Number of IPV vaccines doses	8,101,700	Annual Amounts (US\$)	US\$7,261,000		
Type of supplies to be purchased with Gavi funds in each year	2017							
Number of IPV vaccines doses	8,101,700							
Annual Amounts (US\$)	US\$7,261,000							
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.								
13. Self-procurement: Not applicable.								
<p>14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Nigeria is encouraged to contribute to vaccine and/or supply costs for IPV.</p>								
15. Operational support for campaigns: Not applicable								

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This is the amount that Gavi has approved.

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May and August
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Country shall provide the following clarifications to Gavi*:

Not applicable.

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the presentation and actual number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

16 December 2016

NIGERIA -- Support for Injection Safety Devices
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nigeria					
2. Grant number: 17-NGA-32a-X; 18-NGA-32a-X; 19-NGA-32a-X; 20-NGA-32a-X					
3. Date of Decision Letter: 16 December 2016					
4. Date of the Partnership Framework Agreement: 9 January 2014					
5. Programme title: Injection Safety Devices ¹					
6. Programme duration²: 2017-2020					
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)					
	2017	2018	2019	2020	Total ³
Programme Budget (US\$)	1,766,000	1,252,000	999,500	725,500	4,743,000
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
TOTAL immunisation supplies to be purchased with Gavi funds in each year		2017			
Number of AD syringes		35,028,000			
Number of safety boxes		385,350			
Annual Amounts for immunisation supplies for all Gavi vaccines (US\$)		1,766,000			
Immunisation supplies to be purchased with Gavi funds in each year, <u>by type of support</u>					
New Vaccine Support (NVS), Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID,Routine		2017			
Number of AD syringes		14,865,900			
Number of safety boxes		163,550			
Annual Amounts for immunisation supplies for Vaccine (US\$)		749,500			

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID,Routine	2017	
Number of AD syringes	12,676,100	
Number of safety boxes	139,450	
Annual Amounts for immunisation supplies for Vaccine (US\$)	639,000	
New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID,Routine	2017	
Number of AD syringes	7,486,000	
Number of safety boxes	82,350	
Annual Amounts for immunisation supplies for Vaccine (US\$)	377,500	
9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
10. Self-procurement: Not applicable.		
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.		

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

16 December 2016